PRNewsWire
05 Aug 2026, 08:28 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance for its TTR product due to normalizing growth in second-line volume. — A reduction in revenue guidance for a core product directly impacts valuation and indicates slower-than-expected market penetration.
-0.80Schall, Brown & Schwartz LLP has launched an investigation into Alnylam for potential securities law violations and misleading statements. — Legal investigations and potential class-action lawsuits create overhang, regulatory risk, and can damage investor confidence.
-0.40Which stocks this story touches
The company is under investigation for securities law violations following a 28.4% stock price drop and lowered sales guidance.
Continue reading
6 related stories
Search tags
The company is mentioned as being subject to a fraud investigation by SBS Law.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
